TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency ("Fitch") has raised the Company's corporate credit rating to BB+, with a stable outlook; from BB.
Fitch's report cites Teva's progress in reducing debt and improving flexibility, expects continuous revenue growth from AUSTEDO and AJOVY, as well as Teva's biosimilar pipeline. In addition, Fitch mentions that Teva's focus on optimizing external spend, prioritizing resource allocation, and modernizing its organization is expected to lead to higher operating margins.
"We are proud to receive a second consecutive upgrade from Fitch within several months, especially coming on the heels of Moody's upgrade last Friday. This recognition reflects the strength of our financial discipline and the unwavering commitment of our teams. It's a powerful endorsement of our Pivot to Growth strategy and a clear signal of confidence in our future," said Eli Kalif, Chief Financial Officer, Teva Pharmaceuticals.
About Teva
Teva Pharmaceutical Industries Ltd..
Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned "Risk Factors" and "Forward Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
| Teva Media Inquiries | TevaCommunicationsNorthAmerica@tevapharm.com (mailto:TevaCommunicationsNorthAmerica@tevapharm.com) |
| Teva Investor Relations Inquiries | TevaIR@Tevapharm.com (mailto:TevaIR@Tevapharm.com) |
